You just read:

Celtic Pharma Announces Completion of Enrollment in Dose Tolerance Trial Evaluating XERECEPT® in Pediatric Patients with Primary and Metastatic Brain Tumors

News provided by

Celtic Pharmaceutical Holdings L.P.

Oct 03, 2011, 08:00 ET